GSK, Amgen and AstraZeneca released positive data supporting their rival drugs in a condition called chronic rhinosinusitis ...

HHS Assistant Secretary of Public Affairs Tom Corry unexpectedly stepped down on Feb. 28. In a brief post on X Monday morning ...

In the SWIFT and ANCHOR trials, depemokimab demonstrated statistically significant reductions in nasal polyp size, ...

Emerging tools enable more accurate antigen production and presentation using mRNA instead of protein. In recent years, mRNA technology has come into its own, most prominently in the field of vaccine ...

The US Food and Drug Administration (FDA) has accepted for review GSK’s Biologics License Application for depemokimab.

Pharmaceutical majors AstraZeneca and GSK have partnered with competitor Takeda and nine suppliers to accelerate the adoption ...

FDA reviews GSK depemokimab for asthma and CRSwNP, with a decision expected by December 2025. Phase 3 data shows improvements ...

Already billed as a potential blockbuster, Amgen and AstraZeneca’s Tezspire has turned in strong clinical data in chronic ...

Amgen and AstraZeneca's Tezspire showed significant reductions in nasal polyp severity, congestion, and surgery need in CRSwNP patients in the Phase 3 WAYPOINT trial.

Now biometric authentication in your home state is possible when you do GST registration in another state, GSTN Advisory on ...

New data shows Australia's gender pay gap has narrowed, but working women are still more than $28,000 a year worse off than ...

The higher prices of two COPD inhalers from GSK that are targeted in the second round of government drug price negotiations ...